FTC Act Section 5 for CPG
The FTC Act bars deceptive advertising: objective claims need a reasonable basis before they run, and qualifications and material terms must be clear and conspicuous so the net impression is not misleading.
U.S. Federal Trade Commission (FTC) · United States
Clinical-proof claims, testimonials and endorsements for CBD products must be backed by fitting evidence, reflect typical results and disclose material connections.
FTC Act 5, 12 (15 U.S.C. 45, 52); FTC Advertising Substantiation Policy Statement; 16 CFR Part 255; FTC Health Products Compliance Guidance (2022)
Clinical-proof claims, testimonials and endorsements for CBD products must be backed by fitting evidence, reflect typical results and disclose material connections. Apply to US CBD and cannabinoid marketing that uses clinical-proof language, studies, testimonials, reviews, doctors or influencers. This guide summarizes the supplied rule information for marketing review. Use the linked official source to confirm the current text, applicability and
US Federal
Read official sourceLast reviewed: 2026-11-05
General information, not legal advice.
general_audience, general_adults_18plus, adults_21plus, customers · Cannabis, Cannabis (CBD), CBD · advertising marketing
United States
all_channels
2026-05-10
Clinical-proof claims, testimonials and endorsements for CBD products must be backed by fitting evidence, reflect typical results and disclose material connections.
Apply to US CBD and cannabinoid marketing that uses clinical-proof language, studies, testimonials, reviews, doctors or influencers.
Clinical-proof claims, testimonials and endorsements for CBD products must be backed by fitting evidence, reflect typical results and disclose material connections.
general_audience, general_adults_18plus, adults_21plus, customers · Cannabis, Cannabis (CBD), CBD · advertising marketing
United States
all_channels
2026-05-10
Request a free compliance scan of your homepage and book a time with Warrant.
Get a free homepage compliance scan